• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

    1/7/25 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email

    TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

    Conference Call Information

    Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company's website for at least 30 days.

    About Regeneron

    Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

    Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

    For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

    Contact Information:  
    Investor RelationsCorporate Communications
    Ryan CroweChristina Chan
    914.847.8790914.847.8827
    [email protected] [email protected] 


    Primary Logo

    Get the next $REGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    5/30/2025$662.00Outperform → Sector Perform
    RBC Capital Mkts
    5/30/2025$580.00Overweight → Equal Weight
    Wells Fargo
    5/14/2025$700.00Neutral → Buy
    Citigroup
    4/22/2025$695.00Overweight
    Cantor Fitzgerald
    2/5/2025$762.00 → $834.00Market Perform → Outperform
    Leerink Partners
    1/16/2025$1130.00 → $738.00Buy → Neutral
    UBS
    12/10/2024$565.00Underperform
    BofA Securities
    11/15/2024$1150.00Outperform
    Wolfe Research
    More analyst ratings

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schenkein David P was granted 166 shares, increasing direct ownership by 59% to 448 units (SEC Form 4)

      4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

      1/6/25 5:42:19 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thompson Craig B. was granted 166 shares, increasing direct ownership by 37% to 620 units (SEC Form 4)

      4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

      1/6/25 4:13:03 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Coles N Anthony was granted 166 shares, increasing direct ownership by 12% to 1,559 units (SEC Form 4)

      4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

      1/6/25 4:12:14 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    SEC Filings

    See more
    • Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

      6/18/25 4:12:21 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Regeneron Pharmaceuticals Inc.

      SCHEDULE 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

      6/5/25 11:11:31 AM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

      13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

      5/2/25 4:15:32 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

      For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

      5/20/22 3:11:09 PM ET
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care